Cargando…
Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension
There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I(2)) (PGI(2)), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI(2)), pho...
Autores principales: | Nakamura, Kazufumi, Akagi, Satoshi, Ejiri, Kentaro, Yoshida, Masashi, Miyoshi, Toru, Toh, Norihisa, Nakagawa, Koji, Takaya, Yoichi, Matsubara, Hiromi, Ito, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928621/ https://www.ncbi.nlm.nih.gov/pubmed/31771203 http://dx.doi.org/10.3390/ijms20235885 |
Ejemplares similares
-
Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2017) -
Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2018) -
Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015) -
Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist
por: Nakashima, Mitsutaka, et al.
Publicado: (2023) -
Impact of malnutrition on prognosis in patients with pulmonary arterial hypertension
por: Nakashima, Mitsutaka, et al.
Publicado: (2023)